Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

OBJECTIVES: I. Characterize the effect of prednisone on muscle protein metabolism in patients with Duchenne muscular dystrophy.

II. Determine whether prednisone changes levels of insulin-like growth factor 1, growth hormone, and insulin.

III. Characterize the effect of prednisone on muscle morphometry and muscle localization of utrophin.

IV. Compare the prednisone response in patients with Duchenne muscular dystrophy to that seen in normal individuals and in patients with facioscapulohumeral dystrophy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Collaborators: National Institute of Neurological Disorders and Stroke (NINDS); University of Rochester
• Treatments: Prednisone

Criteria

PROTOCOL ENTRY CRITERIA:

• Ambulatory males with Duchenne muscular dystrophy

• No medical/psychiatric contraindication to protocol therapy

• No requirement for regular use of prescription medication